GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.64
0.15 (2.00%)
▲
5d:
+0.0%
30d:
-0.91%
90d:
-2.18%
HOLD
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.44
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.83
29.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.64, which is considered oversold relative to its 30-day fair value range of $7.54 to $8.13. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.3) compared to its historical average (6.2). Remarkably, the market is currently pricing in an annual earnings decline of 5.1% over the next few years. This pessimistic expectation contrasts with the company's recent 43.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a strong downtrend. Immediate support is located at $7.26, while resistance sits at $7.93.
Market Sentiment: GRFS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.87 (+42.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GRFS is in a strong downtrend. Immediate support is located at $7.26, while resistance sits at $7.93.
Market Sentiment: GRFS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.87 (+42.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.54 -
$8.13
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.2% below Wall St target ($10.87)
Trading Range Analysis
30-Day Trading Range
$7.54 -
$8.13
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.26
Resistance Level
$7.93
Current Trend
Strong Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.29
Wall Street Target
$10.87
(+42.2%)
Revenue Growth (YoY)
-4.8%
Earnings Growth (YoY)
43.5%
Profit Margin
5.6%
Valuation Discount vs History
-5.1% cheaper
PE vs Historical
5.3 vs 6.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.1%
(market-implied from PE analysis)
1-Year Target
$7.25
(-5%)
2-Year Target
$6.88
(-10%)
3-Year Target
$6.53
(-15%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$7.65
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 36.0%)
$79.70
(+943%)
Base:
(SPY PE: 5.3, Growth: 36.0%)
$19.23
(+152%)
Bear:
(PE: 4.5, Growth: 36.0%)
$16.35
(+114%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 10.70 | Current EPS (TTM): $0.70
Bull Case
$16.48
(+116%)
Analyst growth 100.0%, PE expands to 11.8
Base Case
$14.98
(+96%)
Market implied 100.0%, PE stable at 10.7
Bear Case
$5.09
(-33%)
Severe decline -20.0%, PE contracts to 9.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.3 to 6.2
Stabilization Target:
$8.96
(+17.2%)
PE Expansion Potential:
+17.2%
Share & Embed Analysis
Last updated: June 14, 2026 3:04 AM ET
Data refreshes hourly during market hours. Next update: 4:04 AM
Data refreshes hourly during market hours. Next update: 4:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1215 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 53 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$352 | 62 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$219 | 61 BUY |
